Many neurological diseases are progressive in nature, making timely treatment crucial to better quality of life and more time with loved ones. Now, biomarker testing is becoming a critical tool in both the diagnosis and treatment of neurological diseases. This more personalized approach to care emphasizes the need for policymakers to prioritize access to testing and treatment.
